At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 13 enrolled
Drug / intervention
JMI-001 (SJP-304 and SJP-223) +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Double-blind Placebo-controlled 4-Way Crossover Study to Evaluate the Efficacy of JMI-001 (an Over-the-counter Pain Medicine and an Antihistamine) in the Prophylaxis of Veisalgia in Healthy Volunteers
In Brief
A Phase 2 clinical trial evaluating JMI-001 (SJP-304 and SJP-223), SJP-304, and 2 other interventions for Veisalgia. Completed, enrolled 13 participants.
Detailed Summary
The purpose of this study is to determine the safety and efficacy of a combination product for the prevention of veisalgia. Common symptoms of veisalgia following the moderate consumption of alcohol includes headache, fatigue, and thirst. It is the investigators hypothesis that a combination of two drugs can alleviate or significantly reduce these symptoms when taken before the start of moderate alcohol consumption.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsVeisalgia
Countries--
Collaborators--
Timeline
Phase 2CompletedFinished
20162017201820192020202120222023202420252026
Enrollment StartMar 2016
First PostedApr 2016
Primary CompletionMay 2016
TodayJul 2026
First PostedApr 13, 2016
Enrollment StartMar 1, 2016
Primary CompletionMay 1, 2016
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 10.2 years ago
Interventions
JMI-001 (SJP-304 and SJP-223)drug
SJP-304drug
SJP-223drug
placebodrug